Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.
NCT01933568
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Inoperable Locally Advanced Non Small Cell Lung Cancer
Interventions
RADIATION:
SABR
DRUG:
Cisplatin
Sponsor
The Netherlands Cancer Institute